Surrozen is a biotechnology company developing therapeutic product candidates that selectively modulate the Wnt signaling pathway to promote tissue repair, with an initial focus on serious ophthalmic diseases including diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. The company's proprietary SWAP platform uses bispecific antibodies to create potent, selective Wnt-mimetic therapeutics that overcome the manufacturing challenges of natural Wnt proteins, and enables combination of Wnt agonism with other validated mechanisms such as VEGF and inflammatory pathway antagonism in single multifunctional molecules. Surrozen generates revenue through milestone payments and royalties on net sales from collaboration partners like Boehringer Ingelheim, as well as through sublicense arrangements under its core technology patents.